Quantcast

Reportlinker Adds Antibiotics – Global Trends

November 18, 2009

NEW YORK, Nov. 18 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Antibiotics – Global Trends

http://www.reportlinker.com/p0164263/Antibiotics—Global-Trends.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Long-term growth in the global antibiotics market would be affected by two major factors – antibiotic resistance and generic competition. Antibiotic resistance, which compels reduction in the usage of antibiotics, represents the primary market inhibitor. In recent times, there has been a decline in antibiotic prescriptions for respiratory related infections. Another factor that could have a strong bearing on the market is the rising generic competition.

These and other market data and trends are presented in “Antibiotics: Global Trends” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

ANTIBIOTICS BMR-1063

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4

Antibiotic Resistance and Generic Competition to Impact Long

Term Growth 4

3. MARKET DYNAMICS 4

Anti-Bacterials Segment Drives Global Anti-Infectives Market 4

Antibiotic Resistance – A Primary Growth Inhibitor 5

Antibiotic-Resistant Bacteria by Type 5

Patent Expiries Commoditize Antibiotics 6

Patent Expiries of Leading Drugs in the Current and Future 6

Anti-MRSA Antibiotics Find Their Way 6

Key Antibiotics in Pipeline 7

4. COMPETITION 7

Highly Competitive Market 7

GlaxoSmithKline – The Undisputed Leader of Penicillin Market 8

GlaxoSmithKline Leads Cephalosporin Market 9

Pfizer Dominates Macrolides Market 9

Levaquin/Tavanic – The Most Preferred Quinolone Antibiotic 10

Merck Rules Carbapenems Market 11

5. PRODUCT FACTS 11

Penicillin 11

Cephalosporins 12

Macrolides 12

Quinolones 12

Carbapenems 12

Other Antibiotics 12

Aminoglycosides 12

Tetracyclines 13

Sulfonamides 13

Mupirocin 13

Glycopeptides 13

Synercid 13

Oxazolidinones 13

Linezolid 14

6. RESEARCH FINDINGS 14

Cephalosporins Effective when Compared to Penicillin 14

FDA Bans Baytril Antibiotic for Chickens 14

Erythromycin Along with Some Specific Drugs Increase Risk of

Sudden Death 15

Rise in Usage of Quinolones for Urinary Tract Infections Leads

to Drug Resistance 15

7. CORPORATE DEVELOPMENTS 15

3i to Buy Alpharma Unit 15

NCPC to Acquire Stake in DSM’s Antibiotics Division 16

ULL Establishes New Antibiotics Unit in Himachal Pradesh 16

Biocat to Expand Presence in the Indian Market 16

PRWT Acquires Cherokee Chemical Unit from Merck 16

CSPC Joins Hands with Indonesian Firms 16

MIT Scientists Develop a New Antibiotic, Rhodostreptomycin 17

Watson Pharma Introduces Biaxin XL’s Generic Version 17

MiddleBrook Obtains NDA Approval for MOXATAG(TM) 17

Nisshin-Kyorin to Merge with Kyorin Pharmaceutical 17

Schering-Plough Acquires Organon BioSciences 17

GSK & Anacor Partner for Boron Chemistry- Based Antibiotics

and Antivirals 18

Iroko Bags Canadian Rights to Vancocin® 18

Cubist Licenses CUBICIN Rights to Merck 19

Sagent Partners with Astral to Develop Injectable Antibiotics 19

MR Healthcare to Manufacture New Antibiotics & Medicines 19

Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo 19

C&O Pharmaceutical to Distribute Meiact in China 20

Bioton Signs Deal to Market Antibiotics in Russia 20

Toyama Gains Marketing Approval for Geninax® in Japan 20

Forest Laboratories Acquires Cerexa 20

Oscient Modifies Licensing Agreement With LG Life Sciences 20

Orchid Sign Licensing & Distribution Pact With Actavis 21

Forest Laboratories Revokes Partnership With Replidyne 21

SRI and Blanca Collaborate To Develop & Test Carbacephem 21

AstraZeneca To Expand Research Center for Antibiotics 21

Jade Pharmaceutical Begins Levofloxacin’s Production in China 22

Reyoung To Start Antibiotic Production at New Facility 22

Toyama Begins T-705 Clinical Trials 22

SmPC For Sanofi-Aventis’ Ketek® Updated 22

Lupin Receives Approval for Cefpodoxime Proxetil Antibiotic

Tablets in France 22

Antibiotice Plans To Infuse Funds for Antibiotics Production 23

UAE Approves Pfizer’s Zithromax SD 23

Toyama Launches New Garenoxacin Quinolone Antibiotic 23

Wockhardt to Introduce Cefprozil in the US 23

MSD India Launches Invanza in India 24

Orchid Chemicals to Introduce Three New Drugs in the US 24

DUSA Pharmaceuticals Releases ClindaReach(TM) 24

Mylan Releases Cipro’s Generic Version 24

Macrolide Antibiotic Developed in the US 24

University of Michigan Devises NMR Spectroscopy For Antibiotics 24

Glycopeptide-Cephalosporin Antibiotics Developed in the US 25

Neosil Tests NEO 101 Antibiotic 25

New Antibiotic Developed By Canadian Inventors 25

Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada 25

Penicillin Binding Protein Found In Japan 25

Venus Remedies Releases Mucomelt-Forte 25

J&JPRD Seeks FDA Approval for Doripenem Antibiotic 25

J&JPRD Seeks FDA Approval for Investigational Antibiotic,

Ceftobiprole 26

GSK Receives Approval for ALTARGO® in Europe 26

APL Receives FDA Approval for Cefpodoxime Proxetil 26

Cubist Receives Approval to Market CUBICIN in Canada 26

Cubist Obtains Approval to Market CUBICIN for Added

Indications in EU 27

Cubist Gains Approval for CUBICIN in Taiwan and South Korea 27

Cethromycin Achieves FDA’s Orphan Drug Designation 27

8. MAJOR PLAYERS 28

Abbott Laboratories (USA) 28

Bayer HealthCare AG (Germany) 28

Bristol-Myers Squibb Co. (USA) 28

Cubist Pharmaceuticals, Inc. (USA) 29

Daiichi Sankyo Company, Limited (Japan) 29

Eli Lilly and Co. (USA) 29

GlaxoSmithKline Plc (UK) 30

Johnson & Johnson (USA) 30

Kyorin Pharmaceutical Co., Ltd. (Japan) 31

LG Life Sciences Limited (Korea) 31

MiddleBrook(TM) Pharmaceuticals, Inc. (USA) 31

Novartis AG (Switzerland) 32

Pfizer Inc. (USA) 32

Pliva d.d. (Croatia) 32

Roche (Switzerland) 33

Sanofi-Aventis SA (France) 33

Takeda Pharmaceutical Company, Ltd. (Japan) 33

Toyama Chemical Co., Ltd. (Japan) 34

Wyeth Pharmaceuticals, Inc. (USA) 34

9. GLOBAL MARKET ANALYTICS 34

10. THE UNITED STATES 40

Competition 41

11. CANADA 42

12. JAPAN 43

13. EUROPE 44

a. France 46

b. Germany 48

c. Italy 49

d. The United Kingdom 50

e. Spain 51

f. Rest of Europe 52

14. ASIA-PACIFIC 53

India 53

Rising Prices of Penicillin G to Affect Antibiotics Production 53

15. REST OF WORLD 54

EXHIBITS

Table 1: Percentage Breakdown of Leading Antibiotics

Manufacturer Value Sales in the World – 2006

Table 2: Percentage Breakdown of Leading Antibiotics

Manufacturers within Penicillin Class in the World – 2006

Table 3: Percentage Breakdown of Leading Antibiotics

Manufacturers within Cephalosporin Class in the World – 2006

Table 4: Percentage Breakdown of Leading Antibiotics

Manufacturers within Macrolide Class in the World – 2006

Table 5: Percentage Breakdown of Leading Antibiotics

Manufacturers within Quinolone Class in the World – 2006

Table 6: Percentage Breakdown of Leading Antibiotics

Manufacturers within Carbapenem Class in the World – 2006

Table 7: Global Antibiotics Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 8: Percentage Breakdown of Global Antibiotics Market by

Region for the Years 2008 & 2012

Table 9: Global Penicillin Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 10: Percentage Breakdown of Global Penicillin Market by

Region for the Years 2008 & 2012

Table 11: Global Cephalosporin Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 12: Percentage Breakdown of Global Cephalosporin Market

by Region for the Years 2008 & 2012

Table 13: Global Macrolide Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 14: Percentage Breakdown of Global Macrolide Market by

Region for the Years 2008 & 2012

Table 15: Global Quinolones Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 16: Percentage Breakdown of Global Quinolones Market by

Region for the Years 2008 & 2012

Table 17: Global Carbapenems Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 18: Percentage Breakdown of Global Carbapenems Market by

Region for the Years 2008 & 2012

Table 19: Global Other Antibiotics Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 20: Percentage Breakdown of Global Other Antibiotics

Market by Region for the Years 2008 & 2012

Table 21: Percentage Breakdown of Leading Antibiotics

Manufacturer Value Sales in the US – 2006

Table 22: Antibiotics Market by Segment in the US: 2007-2015

(Sales in US$ Million)

Table 23: Percentage Breakdown of Antibiotics Market by

Segment in the US for the Years 2008 & 2012

Table 24: Antibiotics Market by Segment in Canada: 2007-2015

(Sales in US$ Million)

Table 25: Percentage Breakdown of Antibiotics Market by

Segment in Canada for the Years 2008 & 2012

Table 26: Antibiotics Market by Segment in Japan: 2007-2015

(Sales in US$ Million)

Table 27: Percentage Breakdown of Antibiotics Market by

Segment in Japan for the Years 2008 & 2012

Table 28: Antibiotics Market by Region in Europe: 2007-2015

(Sales in US$ Million)

Table 29: Percentage Breakdown of Antibiotics Market by Region

in Europe for the Years 2008 & 2012

Table 30: Antibiotics Market by Segment in Europe: 2007-2015

(Sales in US$ Million)

Table 31: Percentage Breakdown of Antibiotics Market by

Segment in Europe for the Years 2008 & 2012

Table 32: Antibiotics Market by Segment in France: 2007-2015

(Sales in US$ Million)

Table 33: Percentage Breakdown of Antibiotics Market by

Segment in France for the Years 2008 & 2012

Table 34: Antibiotics Market by Segment in Germany: 2007-2015

(Sales in US$ Million)

Table 35: Percentage Breakdown of Antibiotics Market by

Segment in Germany for the Years 2008 & 2012

Table 36: Antibiotics Market by Segment in Italy: 2007-2015

(Sales in US$ Million)

Table 37: Percentage Breakdown of Antibiotics Market by

Segment in Italy for the Years 2008 & 2012

Table 38: Antibiotics Market by Segment in the UK: 2007-2015

(Sales in US$ Million)

Table 39: Percentage Breakdown of Antibiotics Market by

Segment in the UK for the Years 2008 & 2012

Table 40: Antibiotics Market by Segment in Spain: 2007-2015

(Sales in US$ Million)

Table 41: Percentage Breakdown of Antibiotics Market by

Segment in Spain for the Years 2008 & 2012

Table 42: Antibiotics Market by Segment in Rest of Europe:

2007-2015 (Sales in US$ Million)

Table 43: Percentage Breakdown of Antibiotics Market by

Segment in Rest of Europe for the Years 2008 & 2012

Table 44: Antibiotics Market by Segment in Asia Pacific:

2007-2015 (Sales in US$ Million)

Table 45: Percentage Breakdown of Antibiotics Market by

Segment in Asia Pacific for the Years 2008 & 2012

Table 46: Antibiotics Market by Segment in Rest of World:

2007-2015 (Sales in US$ Million)

Table 47: Percentage Breakdown of Antibiotics Market by

Segment in Rest of World for the Years 2008 & 2012

COMPANIES PROFILED

To order this report:

Antibiotics – Global Trends

http://www.reportlinker.com/p0164263/Antibiotics—Global-Trends.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)-652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus